Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
Crossref DOI link: https://doi.org/10.1007/s11523-022-00928-4
Published Online: 2022-11-05
Published Print: 2023-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Huang, Yen-Hsiang
Hsu, Kuo-Hsuan
Tseng, Jeng-Sen
Yang, Tsung-Ying
Chen, Kun-Chieh
Su, Kang-Yi
Yu, Sung-Liang
Chen, Jeremy J. W.
Chang, Gee-Chen
Text and Data Mining valid from 2022-11-05
Version of Record valid from 2022-11-05
Article History
First Online: 5 November 2022